ERBB2 and ovarian cancer: Notably, anti-HER2 CAR-Ms elicited selective cytotoxicity in breast and ovarian cancer models, while integration of CD147 signalling enhanced MMP expression, facilitating ECM degradation and T-cell infiltration [287, 328].